Europe — EMA
Palonosetron Accord
Palonosetron, the active ingredient in Palonosetron Accord, is a 5‑HT3 receptor antagonist presented as a sterile injectable solution for intravenous use.
Request sourcing
What is Palonosetron?
Palonosetron, the active ingredient in Palonosetron Accord, is a 5‑HT3 receptor antagonist presented as a sterile injectable solution for intravenous use. It is used to prevent nausea and vomiting associated with chemotherapy and postoperative recovery in adult patients. GNH USA supplies Palonosetron Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.
GNH USA supplies Palonosetron Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.
What is Palonosetron used for?
Palonosetron is indicated for the prevention of nausea and vomiting in several clinical settings related to the 5‑HT3 pathway.
- Chemotherapy‑induced nausea and vomiting (CINV): Provides prophylactic control of acute and delayed episodes. - Post‑operative nausea and vomiting (PONV): Reduces the incidence of nausea and vomiting after surgery. - Radiotherapy‑induced nausea and vomiting: Helps manage the symptoms when radiotherapy is emetogenic. - Anticipatory ant ‑ C --- --- --- --- --- --- --- --- --- --- --- - --- --- --- --- ‑ --- --- ---
What are the side effects of Palonosetron?
Palonosetron … … … … … … ... ",
